Medical Devices

LIB Therapeutics' new monthly, room-temperature stable cholesterol drug shows strong long-term data, challenging rivals with a focus on patient ease-of-use.

DERMAFLASH launches its first sonic dermaplaning system for pros, promising a safer, more effective alternative to traditional scalpel-based treatments.

Australian medtech firm 4DMedical lands CE Mark for its revolutionary CT:VQ lung imaging, fueling a major European expansion with a fresh AU$83M investment.

A Georgia firm's painless patch technology earns top honors, promising to revolutionize medicine delivery and solve critical global health challenges.

A $15M grant fuels a revolutionary therapy for a fatal childhood disease, turning patients' own cells into 'living biofactories' to fight MPS I.

After promising results in a key patient subgroup, the PREVAiLS study will test if pridopidine can slow the relentless progression of ALS.

After a major capital overhaul, PAVmed pivots to growth, advancing cancer diagnostics, remote monitoring, and a relaunched device portfolio.

NUCOT celebrates patients thriving 25+ years post-transplant, setting new global benchmarks in survival rates through advanced care and resilience.

A multimillion-dollar expansion in Springfield, MO will make Alltrista a leader in precision medical molding, creating jobs and fortifying supply chains.

Activist investor Irenic Capital is demanding a new committee to oversee Teleflex's strategic review, escalating a public battle over the company's future.

With a fortified balance sheet and promising clinical data, Monopar Therapeutics is advancing its lead drug, ALXN1840, toward a pivotal NDA filing.

As Mochi Health takes the stage at a top women's health summit, a look behind the PR reveals a company battling rapid growth and customer complaints.

After its pivotal trial for ersodetug missed its primary endpoint, Rezolute gets a rare nod from the FDA to submit full data, igniting new hope.

New research on ILUMYA, LEQSELVI, and WINLEVI shows sustained efficacy and faster results, aiming to transform treatment for millions of patients.

A landmark partnership is scaling a 'one-drug, many-diseases' therapy, revealing how logistics, not just labs, are key to the future of medicine.

New 3-year trial data shows UCB's BIMZELX prevents painful flares in most HS patients, highlighting a critical window for early intervention.

After a transformative year, PRF Technologies ditches its old model for a bold new strategy in AI-driven solar analytics and advanced ocular healthcare.

As co-founder Jürgen Bickel steps down, 14-year veteran David Männer takes the helm to navigate Storz & Bickel's future and drive Canopy's U.S. plans.

New data shows Dizal's ZEGFROVY achieved an 81.3% response rate in a lung cancer subgroup with limited options, signaling a potential new first-line standard.

With a fresh Nasdaq listing and $57.2M in funding, Satellos is advancing a novel muscle-regenerating drug for Duchenne into pivotal pediatric trials.